Clinical Trial Update: Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma [Phase 2]

View source ↗

Summary

Phase II study evaluating axitinib (AG-013736) targeting VEGF pathway in metastatic/recurrent/unresectable pheochromocytoma and paraganglioma has completed with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• Axitinib (Axitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Pheochromocytoma, Paraganglioma | Phase 2 | Status: COMPLETED | Results posted: 2020-08-31